论文部分内容阅读
急性心肌梗塞(AMI)后采用溶栓疗法,已使住院病死率由10年前的12%～20%降至5%～10%。当今正在研究辅助治疗,以期增强溶栓效果,并增加安全系数。降低心肌耗氧量β阻滞剂:当今主张溶栓疗法配合β_1阻滞剂,首先静注,继以口服。据证明,静注阿替洛尔(atenolol)5～10mg,继以口服每日100mg,可使7日病死率下降14%(P<0.02)。有人认为,这可预防 AMI 后心脏破裂。或可用美托洛尔(metoprolol)15mg 静注,继以口服每日100～200mg。
Thrombolytic therapy after acute myocardial infarction (AMI) has reduced in-hospital mortality from 12% to 20% 10 years ago to 5% to 10%. Adjuvant therapy is being investigated today to enhance thrombolytic efficacy and increase safety. Reduce myocardial oxygen consumption β blockers: Today advocated thrombolytic therapy with β 1 blockers, the first intravenous, followed by oral. It has been demonstrated that intravenous injection of atenolol 5 to 10 mg followed by oral administration of 100 mg daily resulted in a 14% reduction in the 7-day mortality rate (P <0.02). Some people think that this can prevent heart rupture after AMI. Or available metoprolol 15mg intravenously, followed by oral daily 100 ~ 200mg.